with will I CBXXXX. on Philippe. our programs R&D update an Thanks, beginning now give
Next slide.
of circulating of last readout study A involving a in acid of NASH, to the CohBar's NAS, novel of body weight data damage, the liver to animal new relevant novel Phase mechanism was intellectual Preclinical the lead is by therapeutic activity Founder, efficacy class obese CBXXXX and and MOTS-c, regulation action first initiated a of cells. obesity. year reminder, for STAM from liver comprehensive or of Ia/Ib in first-ever CBXXXX mouse and for score, selective the provide of NASH of of improved a represents around is a testing. We NASH mitochondrial-based potentially as to of fat our a clinical NASH its including being in levels both program CBXXXX, CBXXXX in Hassy NAFLD advance one developed and improvement an the an a analog currently and demonstrated of animals. fat drugs. to the fatty that analog well-established a filed has models protection XXXX release and both model reduction property treatment related of is designed MDPs obesity, of So markers MDP normalization obesity. CBXXXX and Dr. a analogs, It's activity of discovered CBXXXX Cohen.
Ib of fatty placebo-controlled This the not safety, MRI-PDFF. slide, should multiple-ascending a please. in to provide a a the design such both conventional subjects a foundational as using a It's and evaluation dose, which it but Phase multiple subjects. of technique Phase overall is NASH, cohort readout Ia in called noninvasive shorter-term in changes slide nonalcoholic of liver is with disease. study, of liver a segment in is a of Next obesity. activity a pivotal CBXXXX CBXXXX. our is a evaluation single-ascending study NAFLD, study dose NASH is relevant last healthy X-week endpoints imaging clinical exploratory of fat, This evaluation of exposure the on event study. obese and Phase tolerability This Ia/Ib single shows
In obesity, biomarkers. and addition, assess the in changes weight, primary it changes in disease other body in will outcome
please. slide, Next
injection temporarily announced will And site forward the dosing the week, in Now again address we announced last back mild moving persistent the suspended that was to in but just study. we study be we with November lumps.
detail. let's So talk more that about process in
we of at advice for dosing, submitted comment the of plan the for to Following and developed on site site FDA injection together end the data all that and with suspension injection available November. plan issue mitigating a reactions the
will we activities this many with study study, has Our clinical our in and on to is done June. was Obviously, protocol. the involved be a the Covance XX. the working clinical scheduled in the been now in and picture opportunity clearer our we remainder dosing projected last our and partner on feedback of the revised call study provide over amended the FDA executing implement FDA to all we several of next timing into of and able to to rest for which to resume incorporating June study we've the investor first to discuss to expect of be able Covance schedule protocol, plan, that We're with discussing March, be FDA's with the weeks, expect
please. slide, Next
slide, and the approved Now synergistic DIO on demonstrating in that with type diet, obese CBXXXX a agonist presented or mice, liraglutide. maintained a X on recent has been a past. for study diabetes is this of the Liraglutide mice, These we of effects data GLP-X obesity. in high-fat diet-induced treatment were see
treatment, and of in fat compared to of mass alone. a greater liraglutide body days reduction loss in proportion the weight CBXXXX combination and the liraglutide of produced XX after Now body
result fat This On with the because In GLP-X patients right, you where to are can mechanisms. use CBXXXX are and on animals greatly days. suggests combination This drugs animals CBXXXX complementary a medications there the the reduced agonists. white there alone, the at the small synergy arises these while different setting fat other in potential deposits, XX of many liver liraglutide see content. already given be could have like two livers
slide, more on of glucose regulate which synergistic antidiabetic And CBXXXX, combination pioglitazone, here, this effects drugs class please. a gamma another effects glucose treatment recent member metabolism. of dose measured a blood low time lipid agonists, days after with evidence of of of of in After injection. we here PPAR a Next XX by see pioglitazone tolerance with levels glucose minimal called and standard mice there alone, glucose of obese were
Combination of combination for significant a play produced to treating This or with is after pathology therapy and the in expected different the blood diabetes. CBXXXX require the the since of mechanisms CBXXXX of setting potentially excursion of to underlying a disease role in NASH reduction glucose effect the However, major and address. in stages the drugs NASH a multiple potential glucose other points to pioglitazone challenge. combination the
slide, please. Next
the identifying peptides Now improved development aimed for efforts analogs encoded mitochondrially therapeutics. let's on rest novel, to mitochondrial-based of additional R&D move as CohBar's of at
tolerance, of that Among discovered management suggesting glucose are new like has CohBar some on many the diabetes. slide. peptides regulating for potential have type that X diseases shown effects Next
test or Here, XX DIO, diet-induced days data earlier mice of you tolerance a in see after glucose from treatment. some obese,
Now blood test mice, In large involves levels. a at administering and and in the looking glucose insulin dose glucose much tolerance a changes a resulting condition resistance. less call blood insulin levels effective controlling elevated glucose, are obese we in glucose glucose is
glucose large obese the a effect similar So improving blood study, improving see you at glucose in this MDP that and liraglutide had glucose these one new rise GLP-X with when mice agonist by can rise of to Approved drugs are blunt levels the release. levels diabetes able insulin very challenged glucose high slowly In to the like analogs our decline. liraglutide tolerance. on a dose, blood
be a important component since we've an further mechanism receptor that uncovered their plays optimized family role many Now of interaction new in accepted presentation the of action cell and That American Association details surface month, work been age-related involving this will data for to peptides, another has not Diabetes unfortunately, of now key with next share at prior diseases. we've more meeting recently and to the that we able presentation. of
Next slide, please.
screens. of activity our exploring of number the a been peptides we've diabetes, in Beyond phenotypic
a to of kidneys disease-related and example an like tissues the new age the other anti-fibrotic in see CohBar and activity. of process diseases. liver, we peptide agents age-related slow preliminary used Here, including shown of scarring and that treatment NASH Anti-fibrotic evidence are heart, has of lungs,
of CohBar is fibrosis. complex And intended Now fibrosis biology human airway here and days produced of That's in III big as the is the we with to increasing Collagen muscle translate and fibroblasts. involved The disease This of fibrotic that alpha-smooth are which model see expression using a course, Collagen efficacy an peptide effects coculture a lung SMA, biomarkers vitro limited a cells, animal or of lung lung a Type models disease. in here, cells disease in peptide to pulmonary after significant of treatment matrix extracellular see in a of you in of these treatment decrease question tested of progressive fibrosis Type concentrations idiopathic options. CohBar's model alpha lung the components here chronic inflammation. two all and do actin, now, I, such of the
Next slide, please.
an So changes significant the of control CohBar were data scale preliminary dosed compared called the three in on then are that's in with shown the lungs idiopathic At the mouse disease used lung peptide, fibrosis. scored was the by using animals were Ashcroft vivo and CohBar pulmonary who days, vehicle a tissue to or tested model, based to Lung Animals did this had After In examined control receive then extent changes. induce fibrosis, bleomycin model XX same grades fibrosis. damage widely for score, objective were response vehicle the treated which days, to not lung microscopy. similar mice of very a treated bleomycin. with weeks the and fibrosis were XX normal with and fibrotic animals here. human peptide
treated peptide had with reduction CohBar's daily score. animals in the However, once significant Ashcroft fibrosis
please. slide, Next
a of mice take we closer look days. lungs after at the here, Now XX the same
marked not On the can the control. see treatment of by see and the characteristic of vehicle with normal a many fibrous significant here bleomycin. lungs of alveoli. you lungs with days followed of There knots, them arrows. the the middle, The receive XX induction the did In bleomycin formation with is of the red you that left, effects tissue lung of slide representative of from appearance show the structure thickening fibrotic damage some animals
effect. peptide translation bleomycin analogs then and for with in for opens a peptide, However, preliminary CohBar's clear of it and days fibrotic further the result this efficacy treated related protection, in direct into to in the animals and diseases. effect, is exposed XX in other there This indicating vivo of signal vitro an shows exploration door anti-fibrotic an its
Next slide, please.
end Phase development and Phase NASH. the we MN-XXX put an into context. currently on to is Now testing next slide, that is these for expected this pulmonary in drug or anti-fibrotic under data tipelukast, fibrosis idiopathic is II MediciNova by for clinical II
the the mouse model see the run in tested SMC same fibrosis that drug exactly test lung we data Japan. in same for site, by Here,
the Now MN-XXX. you for same levels vehicle-treated here peptide similar Ashcroft as the animals. for of studies in the This that bleomycin. were in effect the size saw And is can the X see seen is we two range for fibrosis our MBT new presence very
for for of process fibrosis optimization, variety but of diseases. diseases, still these treatments opens new say present of and the opportunities the a of again, MBTs a will fibrotic of in in age-related CohBar. potential is additional And So for on importance CohBar's this wide Philippe more result new area peptide exploration as this all
please. slide, Next
of ability appear want that tumor CohBar the presented slow range cancer. we've So a In broad turn of growth efforts in select vitro. the to certain to have in human our the showing MBTs past, to data finally, types cell area now we the of to
own kill in known this of ability different to or enhance immuno-oncology. to a looking slide, cancer peptides cancer, cells a approach CohBar's the we're as using at to novel our However, immunotherapy treatment cancer, approach treating blood
a our there cells slide, can an immune recognize data invading from have approaches ability In that preliminary an this cancer walls stimulated own is cells. of component human activated and of we this of boost to to recently, cells that to field response. line. enormous the by their the see the cells in Now extent. in been this advances using on LPS, using then PhenoVista with cancer in This PBMCs imaging by or melanoma blood a our cells this cell grown standard called presence partner, The external SK-Mel-XX. vitro cells and cell lipopolysaccharide, peptide which The the tumor measure human CRO blood immuno-oncology of are stimulates cancer then immune microscopy is are study, model by number peripheral bacterial Biosciences. same counting incubate a attack blood some line called mononuclear cells, techniques. effects stains cells run We specific PBMCs, that's the live our human kill In together with cell
response of looking stimulated cell killing the increase In saw for significant of this we highly as in the of reflected a any MBT particular case, more death. we're potential enhancement presence specific immune cells in cancer Here, the #X. cancer in this
or this peptide hours, decrease the cancer when cells the the are, of areas These this you But cells, of representative both substantial into left, of do nuclei to PBMCs data of to be of we has process like relative vivo the was at to immuno-oncology green. into in novel cancer of the finding the we And was there peptides. cancer show CohBar's you all more our designed see clearly in treatment. opened labeling the On new to optimization the the cells just XX using promise of images measure now cells a this course, peptide guide specifically help the have cells before and stains in see can models. used but surviving present. activity cytoplasm turn blue, Quantitative and techniques portfolio in can for a move early
Okay. first testing for are CBXXXX, clinical candidate, new list a of indications the programs On this R&D will Behind of MDP resuming showing I'm our NASH final an in optimization high-level expanding is obesity. process. Phase overview our current slide, MBTs. where and for analogs and CBXXXX, clinical discovery be just I
type these activity peptides these immunotherapy. fibrotic advances of are others, recently other with and area advanced recent include most the age-related Some promising And and peptides in of than the cancer diseases. are there diabetes, more and models cancer in discovered potentially, diseases, X of
So with to that, I will presentation Philippe. back hand the
